Abstract:Key PointsSignal transducer and activator of transcription (STAT) proteins have dual roles: they transduce signals through the cytoplasm and function as transcription factors in the nucleus. Although some STAT proteins such as STAT1 increase anti-tumour immunity, STAT3 and others induce cancer-promoting inflammation.STAT3 signalling is a major intrinsic pathway for cancer inflammation owing to its frequent activation in malignant cells and key role in regulating many genes crucial for cancer inflammation in the tumour microenvironment.Persistent activation of STAT3, and to a lesser extent STAT5, in diverse human cancers increases proliferation, survival, angiogenesis and metastasis, while also inhibiting anti-tumour immunity.Many STAT3-regulated genes encode cytokines and growth factors, the receptors of which in turn activate the same STAT3 pathways, thereby propagating a stable feedforward loop between tumour cells and non-transformed stromal cells, including myeloid cells and T cells, promoting inflammatory responses that further support tumour growth and survival.Interleukin-6 (IL-6)–Janus kinase (JAK)–STAT3 signalling is important for cancers resulting from the activation of the intrinsic inflammatory pathway owing to genetic or epigenetic changes in tumour cells. Extrinsic environmental inflammatory factors such as sunlight, pathogens and chemical carcinogens can also activate STAT3 through different mechanisms.STAT3 interacts with nuclear factor-κB (NF-κB) at multiple levels and is activated by several NF-κB-regulated gene products, including IL-6. These two transcription factors regulate a multitude of genes important for STAT3 activation and cancer-promoting inflammation.STAT1-driven anti-tumour immune responses and STAT3-mediated immune modulatory pathways can be mutually antagonistic, suggesting that therapeutic interventions targeting specific STATs can tip this balance to convert tumour-promoting inflammation to anti-tumour immune responses. Therefore, STAT3 has emerged as a crucial target for cancer therapy and STAT3 inhibitors are actively being developed.Several tyrosine kinase inhibitors already in the clinic reduce STAT3 signalling by various mechanisms, thereby inducing tumour cell apoptosis and modulating inflammation in the tumour microenvironment in favour of therapeutic responses.

Regulation of the IL-23 and IL-12 Balance by Stat3 Signaling in the Tumor Microenvironment

Regulation of the IL-23 and IL-12 Balance by Stat3 Signaling in the Tumor Microenvironment

Interleukin 33 in Tumor Microenvironment is Crucial for the Accumulation and Function of Myeloid-Derived Suppressor Cells

IL-23 stabilizes an effector T reg cell program in the tumor microenvironment

Hmgb1-IL-23-IL-17-IL-6-Stat3 Axis Promotes Tumor Growth in Murine Models of Melanoma

Increased Th17 cells in the tumor microenvironment is mediated by IL-23 via tumor-secreted prostaglandin E2.

Toll-Like Receptor 9 Activation Of Signal Transducer And Activator Of Transcription 3 Constrains Its Agonist-Based Immunotherapy

STATs in cancer inflammation and immunity: a leading role for STAT3

miR-22 promotes immunosuppression via activating JAK/STAT3 signaling in cutaneous squamous cell carcinoma

Interleukin 23 Regulates Proliferation of Lung Cancer Cells in a Concentration-Dependent Way in Association with the Interleukin-23 Receptor.

A Requirement Of Stat3 Dna Binding Precludes Th-1 Immunostimulatory Gene Expression By Nf-Kappa B In Tumors

STAT3-induced S1PR1 expression is crucial for persistent STAT3 activation in tumors

Pharmacologic inhibition of IL11/STAT3 signaling increases MHC-I expression and T cell infiltration

IL-27 Gene Therapy Induces Stat3-Mediated Expansion of CD11b+Gr1+ Myeloid Cells and Promotes Accumulation of M1 Macrophages in the Tumor Microenvironment.

Converged Rab37/IL-6 trafficking and STAT3/PD-1 transcription axes elicit an immunosuppressive lung tumor microenvironment

IL-22 is related to development of human colon cancer by activation of STAT3

Distinct roles for interleukin-23 receptor signaling in regulatory T cells in sporadic and inflammation-associated carcinogenesis

STAT3 restrains dendritic cell function and tumor immunity

Tumoral Expression of IL-33 Inhibits Tumor Growth and Modifies the Tumor Microenvironment Through CD8+ T and NK Cells

IL6/STAT3 Signaling Orchestrates Premetastatic Niche Formation and Immunosuppressive Traits in Lung

Abstract 6966: STAT3 integration of inflammatory signals and cellular stress promote tumor initiation and progression through the expression of integrin β3